posted on 2023-04-03, 14:49authored bySébastien Cornet, Doriane Mathé, Kamel Chettab, Anne Evesque, Eva-Laure Matera, Olivier Trédan, Charles Dumontet
The tumor growth inhibition (TGI) measured on day 56 confirmed the potentiation of trastuzumab antitumor activity when co-injected with pegfilgrastim. Co-treatment with pegfilgrastim and trastuzumab significantly decreased A549 growth when compared to untreated, trastuzumab alone and filgrastim plus trastuzumab groups according to one way ANOVA (p<0,001). In this experiment three mice were used for each group.